Biotech sector having a tough 2016 year. For Q1 YTD performance is -21.24%. Will Q2 ’16 be different or the same? Here are some upcoming PDUFA and Adcomn to Watch for April

IBB chart

IBB1

  1. ICPT- Adcom 4/7 for Obeticholic acid (NDA)Obeticholic acid (NDA), briefing docs out 4/5. Short % of float  22.30%
  2. GILD PDUFA 4/7 F/TAF (NDA). Short % of float 2.33%
  3. CLVS  Adcom 4/12 for Rociletinib (NDA) .  Short % of float 28.72%
  4. CHMA PDUFA 4/15 Mycapssa (NDA). Short % of float 12.93%
  5. PGNX PDUFA 4/19 Oral Relistor (NDA), Short % of float 16.70%
  6. SRPT Adcom 4/25 Eteplirsen (NDA), short % of float 35.02%
  7. COLL  4/26 Xtampza (NDA). Final approval of Xtampza (NDA) for the management of pain severe enough to require daily around-the-clock,
  8. FLML PDUFA  4/30. Short % of float 2.14%

Our calendar to keep track here http://www.precisiontrade365.com/fda-calendar-2/